Advertisement

Topics

A Phase 1 Single-Dose Study to Determine the Effect of ACH-0144471 on Subjects With HI Compared to Healthy Matches

2018-06-19 02:41:11 | BioPortfolio

Published on BioPortfolio: 2018-06-19T02:41:11-0400

Clinical Trials [788 Associated Clinical Trials listed on BioPortfolio]

A Pharmacokinetic (PK) Study of ACH-0144471 Modified Release Prototype Formulations in Healthy Subjects

The purpose of this study is to evaluate and compare the plasma PK profiles of study drug, ACH-0144471, in healthy subjects after administration of a single dose of multiple ACH-0144471 pr...

A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

The purpose of this study is to determine the safety and effectiveness of ACH-0144471 in currently untreated patients with PNH.

The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist

Single center, prospective open label PK and PD study of betrixaban in subjects with mild and moderate hepatic impairment vs healthy volunteers.

BG9928 in Subjects With Hepatic Impairment

The primary objective of the study is to evaluate the effect of hepatic function on the pharmacokinetics of a single oral dose of BG9928 in subjects with mild and moderate hepatic impairme...

A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics

The primary purpose of this study is to investigate the pharmacokinetics (behavior of the compound in the body) of safinamide in patients with different degrees of hepatic (liver) impairme...

PubMed Articles [3672 Associated PubMed Articles listed on BioPortfolio]

An Open-Label, Phase 1 Study to Assess the Effects of Hepatic Impairment on Pomalidomide Pharmacokinetics.

Pomalidomide is an immunomodulatory drug and the dosage of 4 mg per day taken orally on days 1-21 of repeated 28-day cycles has been approved in the European Union and United States to treat patients...

Pharmacokinetics of Rolapitant in Patients With Mild to Moderate Hepatic Impairment.

Rolapitant is a selective and long-acting neurokinin-1 receptor antagonist approved in an oral formulation in combination with other antiemetic agents for the prevention of delayed chemotherapy-induce...

Quantitative estimation of plasma free drug fraction in patients with varying degrees of hepatic impairment: a methodological evaluation.

Quantitative prediction of unbound drug fraction (f) is essential for scaling pharmacokinetics through physiologically-based approaches. However, few attempts have been made to evaluate the projection...

Thiamethoxam induced hepatic energy changes in silver catfish via impairment of the phosphoryl transfer network pathway: Toxicological effects on energetics homeostasis.

Precise coupling of spatially separated intracellular adenosine triphosphate (ATP)-producing and ATP-consuming processes exerts a pivotal role in bioenergetic homeostasis of living organisms, and the ...

Hepatic Gi signaling regulates whole-body glucose homeostasis.

An increase in hepatic glucose production (HGP) is a key feature of type 2 diabetes. Excessive signaling through hepatic Gs-linked glucagon receptors critically contributes to pathologically elevated ...

Medical and Biotech [MESH] Definitions

Cholangiocarcinoma arising near or at the confluence of the right and left hepatic ducts (COMMON HEPATIC DUCT). These tumors are generally small, sharply localized, and seldom metastasizing.

A group of metabolic diseases due to deficiency of one of a number of LIVER enzymes in the biosynthetic pathway of HEME. They are characterized by the accumulation and increased excretion of PORPHYRINS or its precursors. Clinical features include neurological symptoms (PORPHYRIA, ACUTE INTERMITTENT), cutaneous lesions due to photosensitivity (PORPHYRIA CUTANEA TARDA), or both (HEREDITARY COPROPORPHYRIA). Hepatic porphyrias can be hereditary or acquired as a result of toxicity to the hepatic tissues.

A class of nongenotoxic CARCINOGENS that induce the production of hepatic PEROXISOMES and induce hepatic neoplasms after long-term administration.

A rare autosomal recessive disorder of the urea cycle. It is caused by a deficiency of the hepatic enzyme ARGINASE. Arginine is elevated in the blood and cerebrospinal fluid, and periodic HYPERAMMONEMIA may occur. Disease onset is usually in infancy or early childhood. Clinical manifestations include seizures, microcephaly, progressive mental impairment, hypotonia, ataxia, spastic diplegia, and quadriparesis. (From Hum Genet 1993 Mar;91(1):1-5; Menkes, Textbook of Child Neurology, 5th ed, p51)

Professionals skilled at diagnostic testing of hearing, HEARING IMPAIRMENT, and CORRECTION OF HEARING IMPAIRMENT by non-medical or non-surgical means.

More From BioPortfolio on "A Phase 1 Single-Dose Study to Determine the Effect of ACH-0144471 on Subjects With HI Compared to Healthy Matches"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial